Last reviewed · How we verify
Placebo of Anagliptin — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo of Anagliptin (Placebo of Anagliptin) — JW Pharmaceutical. A placebo does not have an active pharmacological mechanism; it is used as a control in clinical trials.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo of Anagliptin TARGET | Placebo of Anagliptin | JW Pharmaceutical | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo of Anagliptin CI watch — RSS
- Placebo of Anagliptin CI watch — Atom
- Placebo of Anagliptin CI watch — JSON
- Placebo of Anagliptin alone — RSS
Cite this brief
Drug Landscape (2026). Placebo of Anagliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-of-anagliptin. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab